WeVote
Log In

Bill

Bill

HR 88

Medical Innovation Acceleration Act of 2025

119th Congress Introduced by Andy Biggs

HR 88 accelerates FDA medical device and drug approvals through expedited pathways and relaxed clinical trial requirements, prioritizing faster market access over comprehensive pre-approval testing.

Introduced in House
0
WeVote Research Nonpartisan
Bill Summary · HR 88

Legislative bill overview

HR 88 streamlines FDA approval pathways for medical devices and pharmaceuticals by expanding expedited review programs and reducing regulatory timelines. The bill increases flexibility for manufacturers in clinical trial design and post-market surveillance requirements while maintaining safety oversight mechanisms.

Why is this important

Faster medical innovation approval could bring treatments to patients more quickly and reduce development costs, potentially increasing investment in breakthrough therapies. However, expedited processes may reduce the depth of pre-market safety data, creating tension between speed and consumer protection—a debate affecting millions of patients relying on rigorous drug vetting.

Potential points of contention

  • Safety vs. speed tradeoff: Abbreviated review timelines may insufficiently test long-term safety profiles, particularly for vulnerable populations
  • Industry favoritism concerns: Expanded expedited pathways could benefit well-resourced pharmaceutical companies over smaller manufacturers, potentially reducing competition
  • Post-market surveillance adequacy: Reduced requirements for tracking adverse events after approval might delay identification of serious side effects in real-world use

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.